Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![$rhhbys Graphic](https://lunarcrush.com/gi/w:26/t:$rhhbys.png) $rhhbys

$RHHBY sees increased social media activity with positive sentiment around gene therapy and oncology research. Engagements are up, indicating growing interest in the cryptocurrency.

### About $rhhbys
A cryptocurrency.  

### Insights [#](/topic/$rhhbys/insights)
- $rhhbys mentions hit X which is XXX% higher than it's daily average.
- $rhhbys creators hit X which is XXX% higher than it's daily average.

### Engagements: XXX [#](/topic/$rhhbys/interactions)
---
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$rhhbys/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$rhhbys/time-series/interactions.tsv)  
**Current Value**: XXX  
**Daily Average**: XX  
**1 Week**: XXXXX +17,403%  
**1 Month**: XXX -XX%  
**1-Year High**: XXXXX on 2025-09-03  
**1-Year Low**: X on 2025-06-16  

| Social Network | X   |
| -------------- | -   |
| Engagements    | XXX |
  

  
  
### Mentions: X [#](/topic/$rhhbys/posts_active)
---
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$rhhbys/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$rhhbys/time-series/posts_active.tsv)  
**Current Value**: X  
**Daily Average**: X  
**1-Year High**: X on 2025-09-30  
**1-Year Low**: X on 2025-05-01  

| Social Network | X |
| -------------- | - |
| Mentions       | X |
  

  
  
### Creators: X [#](/topic/$rhhbys/contributors_active)
---
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$rhhbys/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$rhhbys/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $rhhbys in the last XX hours which is up XX% from X in the previous XX hours
**Daily Average**: X  
**1-Year High**: X on 2025-09-30  
**1-Year Low**: X on 2025-05-01  

**Top assets mentioned**
In the posts about $rhhbys in the last XX hours

[Moderna Inc (MRNA)](/topic/$mrna)

**Top topics mentioned**
In the posts about $rhhbys in the last XX hours

[jacob](/topic/jacob), [$mrna](/topic/$mrna), [stocks healthcare](/topic/stocks-healthcare), [$legn](/topic/$legn), [$vrdn](/topic/$vrdn), [$rhhby](/topic/$rhhby), [ted](/topic/ted), [trails](/topic/trails), [niche](/topic/niche), [$qures](/topic/$qures), [$regns](/topic/$regns), [approved](/topic/approved)

### Top Social Posts [#](/topic/$rhhbys/posts)
---
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"$VRDN Jefferies w XX PT based on competitor $RHHBY not competitive results Enrolment in both trails completed with data in h1'25 TED market is 4B or 8B if early stages are included $VRDN MC is 2B with 560M cash"  
[X Link](https://x.com/Andre_AGTC/status/1979552219230872010) [@Andre_AGTC](/creator/x/Andre_AGTC) 2025-10-18T14:16Z 6072 followers, 1702 engagements


"It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient"  
[X Link](https://x.com/GerardCaelles/status/1977771288660791721) [@GerardCaelles](/creator/x/GerardCaelles) 2025-10-13T16:19Z 1098 followers, 13.9K engagements


"Interesting take on the FcRH5 landscape which seems to be one of $RHHBY's main oncology R&D areas of interest. $MRNA & $LEGN active here"  
[X Link](https://x.com/JacobPlieth/status/1970769553572454869) [@JacobPlieth](/creator/x/JacobPlieth) 2025-09-24T08:37Z 30.9K followers, 4482 engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

$rhhbys Graphic $rhhbys

$RHHBY sees increased social media activity with positive sentiment around gene therapy and oncology research. Engagements are up, indicating growing interest in the cryptocurrency.

About $rhhbys

A cryptocurrency.

Insights #

  • $rhhbys mentions hit X which is XXX% higher than it's daily average.
  • $rhhbys creators hit X which is XXX% higher than it's daily average.

Engagements: XXX #


Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XX
1 Week: XXXXX +17,403%
1 Month: XXX -XX%
1-Year High: XXXXX on 2025-09-03
1-Year Low: X on 2025-06-16

Social Network X
Engagements XXX

Mentions: X #


Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1-Year High: X on 2025-09-30
1-Year Low: X on 2025-05-01

Social Network X
Mentions X

Creators: X #


Creators Line Chart
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $rhhbys in the last XX hours which is up XX% from X in the previous XX hours Daily Average: X
1-Year High: X on 2025-09-30
1-Year Low: X on 2025-05-01

Top assets mentioned In the posts about $rhhbys in the last XX hours

Moderna Inc (MRNA)

Top topics mentioned In the posts about $rhhbys in the last XX hours

jacob, $mrna, stocks healthcare, $legn, $vrdn, $rhhby, ted, trails, niche, $qures, $regns, approved

Top Social Posts #


Top posts by engagements in the last XX hours

Showing only X posts for non-authenticated requests. Use your API key in requests for full results.

"$VRDN Jefferies w XX PT based on competitor $RHHBY not competitive results Enrolment in both trails completed with data in h1'25 TED market is 4B or 8B if early stages are included $VRDN MC is 2B with 560M cash"
X Link @Andre_AGTC 2025-10-18T14:16Z 6072 followers, 1702 engagements

"It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient"
X Link @GerardCaelles 2025-10-13T16:19Z 1098 followers, 13.9K engagements

"Interesting take on the FcRH5 landscape which seems to be one of $RHHBY's main oncology R&D areas of interest. $MRNA & $LEGN active here"
X Link @JacobPlieth 2025-09-24T08:37Z 30.9K followers, 4482 engagements

$rhhbys
/topic/$rhhbys